The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo.

The role of the insulin-like growth factor I receptor (IGF-IR) in programmed cell death has been investigated in vivo in a biodiffusion chamber, where the extent of cell death could be determined quantitatively. We found that a decrease in the number of IGF-IRs causes massive apoptosis in vivo in several transplantable tumors, either from humans or rodents. Conversely, an overexpressed IGF-IR protects cells from apoptosis in vivo. We also show that the same conditions that in vitro cause only partial growth arrest with a minimum of cell death, induce in vivo almost complete cell death. We conclude that the IGF-IR activated by its ligands plays a very important protective role in programmed cell death, and that its protective action is even more striking in vivo than in vitro.

[1]  D. Coppola,et al.  Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. , 1994, Cancer research.

[2]  C. Osborne,et al.  Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. , 1989, Cancer research.

[3]  R. Baserga,et al.  Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. , 1995, Cancer research.

[4]  A. Ullrich,et al.  Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[5]  W. Kaelin,et al.  Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Doupe,et al.  Expression of a specific marker of avian programmed cell death in both apoptosis and necrosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Ruoslahti,et al.  Association of insulin receptor substrate-1 with integrins. , 1994, Science.

[8]  Z. Darżynkiewicz,et al.  The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. , 1993, Cancer research.

[9]  L. Wang,et al.  Distinctive effects of the carboxyl-terminal sequence of the insulin-like growth factor I receptor on its signaling functions , 1993, Journal of virology.

[10]  J. Baker,et al.  Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r) , 1993, Cell.

[11]  R. Baserga.  Oncogenes and the strategy of growth factors , 1994, Cell.

[12]  S. Asa,et al.  Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  G. Evan,et al.  c‐Myc‐induced apoptosis in fibroblasts is inhibited by specific cytokines. , 1994, The EMBO journal.

[14]  D. Fisher.  Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[15]  John Calvin Reed,et al.  Anchorage dependence, integrins, and apoptosis , 1994, Cell.

[16]  W. Rutter,et al.  Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation , 1990, Molecular and cellular biology.

[17]  P. Porcu,et al.  The role of the insulin-like growth factor I receptor in the transformation by simian virus 40 T antigen. , 1994, Oncogene.

[18]  M. Tykocinski,et al.  Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. , 1993, Science.

[19]  C. Rogler,et al.  Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. , 1994, The Journal of biological chemistry.

[20]  W. Lee,et al.  Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis , 1994, Molecular and cellular biology.

[21]  J. Swantek,et al.  An E2F binding sequence negatively regulates the response of the insulin-like growth factor 1 (IGF-I) promoter to simian virus 40T antigen and to serum. , 1994, Oncogene.

[22]  C Collins,et al.  Insulin‐like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. , 1986, The EMBO journal.

[23]  F. Bresciani,et al.  Cell kinetics and growth of squamous cell carcinomas in man. , 1974, Cancer research.

[24]  Renato Baserga,et al.  The biology of cell reproduction , 1985 .

[25]  D. Coppola,et al.  Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts , 1994, Molecular and cellular biology.

[26]  D. Cheresh,et al.  Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  H. Namiki,et al.  Apoptotic cell death induced by serum and its prevention by thiols , 1994, Journal of cellular physiology.

[28]  D. Coppola,et al.  A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor , 1994, Molecular and cellular biology.

[29]  C. Kahn,et al.  The insulin signaling system. , 1994, The Journal of biological chemistry.

[30]  Elizabeth J. Robertson,et al.  Role of insulin-like growth factors in embryonic and postnatal growth , 1993, Cell.

[31]  M. Tykocinski,et al.  Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Coppola,et al.  Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. , 1994, Cancer research.

[33]  P. Scott,et al.  IL-4- and IL-5-dependent protective immunity to Onchocerca volvulus infective larvae in BALB/cBYJ mice. , 1994, Journal of immunology.

[34]  R. Baserga,et al.  The insulin-like growth factor I receptor: a key to tumor growth? , 1995, Cancer research.

[35]  S. Rockwell,et al.  Development of an in vitro assay for the survival of cells suspended from BA1112 rat sarcomas. , 1983, European journal of cancer & clinical oncology.

[36]  S. Bayley,et al.  Induction of apoptosis by adenovirus type 5 E1A in rat cells requires a proliferation block. , 1994, Oncogene.

[37]  J. Barrett,et al.  Regulation of apoptosis by low serum in cells of different stages of neoplastic progression: enhanced susceptibility after loss of a senescence gene and decreased susceptibility after loss of a tumor suppressor gene. , 1994, Cancer research.

[38]  L. Helman,et al.  In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. , 1994, Cancer research.

[39]  M. Rubini,et al.  The role of the IGF‐I receptor in the growth and transformation of mammalian cells , 1994, Cell proliferation.

[40]  M. Rubini,et al.  Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Ferber,et al.  Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain. , 1994, The Journal of biological chemistry.

[42]  R. Lanza,et al.  Xenogenic humoral responses to islets transplanted in biohybrid diffusion chambers. , 1994, Transplantation.